dehydrofelodipine (BioDeep_00000054434)

   

human metabolite Endogenous blood metabolite Chemicals and Drugs


代谢物信息卡片


3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate

化学式: C18H17Cl2NO4 (381.0534582000001)
中文名称: 脱水非洛地平
谱图信息: 最多检出来源 Homo sapiens(blood) 1.45%

分子结构信息

SMILES: CCOC(=O)C1=C(C(=C(N=C1C)C)C(=O)OC)C2=C(C(=CC=C2)Cl)Cl
InChI: InChI=1S/C18H17Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8H,5H2,1-4H3

描述信息

dehydrofelodipine is a metabolite of felodipine. Felodipine is a calcium channel blocker (calcium antagonist), a drug used to control hypertension (high blood pressure). It is marketed under the brand name Plendil by AstraZeneca and Renedil by Sanofi-Aventis. The formulation patent for the substance expired in 2007. AstraZeneca dropped Plendil from its support and AZ&Me free Rx access program in October 2008. (Wikipedia)

同义名列表

4 个代谢物同义名

3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-3,5-pyridinedicarboxylate; Dehydro Felodipine; dehydrofelodipine



数据库引用编号

4 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • George K Dresser, Vincent Wacher, Susan Wong, Harrison T Wong, David G Bailey. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clinical pharmacology and therapeutics. 2002 Sep; 72(3):247-55. doi: 10.1067/mcp.2002.126409. [PMID: 12235445]
  • G K Dresser, D G Bailey, S G Carruthers. Grapefruit juice--felodipine interaction in the elderly. Clinical pharmacology and therapeutics. 2000 Jul; 68(1):28-34. doi: 10.1067/mcp.2000.107524. [PMID: 10945313]
  • J Lundahl, C G Regårdh, B Edgar, G Johnsson. Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. European journal of clinical pharmacology. 1997; 52(2):139-45. doi: 10.1007/s002280050263. [PMID: 9174684]
  • J Lundahl, C G Regårdh, B Edgar, G Johnsson. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. European journal of clinical pharmacology. 1995; 49(1-2):61-7. doi: 10.1007/bf00192360. [PMID: 8751023]
  • D G Bailey, J M Arnold, C Munoz, J D Spence. Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin. Clinical pharmacology and therapeutics. 1993 Jun; 53(6):637-42. doi: 10.1038/clpt.1993.84. [PMID: 8513655]
  • E Blychert. Felodipine pharmacokinetics and plasma concentration vs effect relationships. Blood pressure. Supplement. 1992; 2(?):1-30. doi: NULL. [PMID: 1343111]